Lineage Cell Therapeutics (LCTX) Total Non-Current Liabilities (2010 - 2026)

Lineage Cell Therapeutics has reported Total Non-Current Liabilities for 17 years, with the latest figure at $22.7 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities fell 19.04% year-over-year to $22.7 million; the trailing twelve-month figure through Mar 2026 stood at $22.7 million (down 19.04% YoY), and the FY2025 full-year result was $25.3 million, down 15.69% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $22.7 million, down from $25.3 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $59.3 million in Q1 2022, with the low at $22.7 million in Q1 2026.
• Historically, Total Non-Current Liabilities has averaged $38.3 million across 5 years, with a median of $39.0 million in 2023.
• The largest YoY upside for Total Non-Current Liabilities was 442.02% in 2022 against a maximum downside of 38.14% in 2022.
• Lineage Cell Therapeutics' Total Non-Current Liabilities stood at $51.7 million in 2022, then dropped by 24.61% to $39.0 million in 2023, then dropped by 22.95% to $30.0 million in 2024, then fell by 15.69% to $25.3 million in 2025, then fell by 10.4% to $22.7 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $22.7 million (Q1 2026), $25.3 million (Q4 2025), and $23.7 million (Q3 2025), per Business Quant data.